These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 26748709)

  • 1. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
    Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
    Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
    Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
    Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy.
    Schneider HE; Schmitt LM; Job A; Lankat-Buttgereit B; Gress T; Buchholz M; Gallmeier E
    Neoplasia; 2024 Nov; 57():101038. PubMed ID: 39128273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
    Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
    Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
    Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
    J Virol; 2019 May; 93(9):. PubMed ID: 30787154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
    Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
    Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.
    Sarmento LM; Póvoa V; Nascimento R; Real G; Antunes I; Martins LR; Moita C; Alves PM; Abecasis M; Moita LF; Parkhouse RM; Meijerink JP; Barata JT
    Oncogene; 2015 Jun; 34(23):2978-90. PubMed ID: 25132270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.
    Guo Y; Wang J; Benedict B; Yang C; van Gemert F; Ma X; Gao D; Wang H; Zhang S; Lieftink C; Beijersbergen RL; Te Riele H; Qiao X; Gao Q; Sun C; Qin W; Bernards R; Wang C
    Genome Med; 2021 Oct; 13(1):166. PubMed ID: 34663432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
    Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
    Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.
    Buisson R; Boisvert JL; Benes CH; Zou L
    Mol Cell; 2015 Sep; 59(6):1011-24. PubMed ID: 26365377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic treatment with ATR and CHK1 inhibitors does not substantially increase the mutational burden of human cells.
    Casimir L; Zimmer S; Racine-Brassard F; Goudreau F; Jacques PÉ; Maréchal A
    Mutat Res; 2023; 827():111834. PubMed ID: 37531716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
    Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
    Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA-PK phosphorylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe.
    Ashley AK; Shrivastav M; Nie J; Amerin C; Troksa K; Glanzer JG; Liu S; Opiyo SO; Dimitrova DD; Le P; Sishc B; Bailey SM; Oakley GG; Nickoloff JA
    DNA Repair (Amst); 2014 Sep; 21():131-9. PubMed ID: 24819595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation.
    Hammond EM; Dorie MJ; Giaccia AJ
    Cancer Res; 2004 Sep; 64(18):6556-62. PubMed ID: 15374968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.
    Baranski Z; Booij TH; Cleton-Jansen AM; Price LS; van de Water B; Bovée JV; Hogendoorn PC; Danen EH
    J Pathol; 2015 Jul; 236(3):348-59. PubMed ID: 25757065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATR/Chk1/Smurf1 pathway determines cell fate after DNA damage by controlling RhoB abundance.
    Wang M; Guo L; Wu Q; Zeng T; Lin Q; Qiao Y; Wang Q; Liu M; Zhang X; Ren L; Zhang S; Pei Y; Yin Z; Ding F; Wang HR
    Nat Commun; 2014 Sep; 5():4901. PubMed ID: 25249323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.